Treatment of Multiple Sclerosis with Copolymer I
The most desirable treatment for multiple sclerosis (MS) would safely arrest the disease process before clinical signs and symptoms had appeared. This has not yet been achieved. Failing this, one would wish safely to arrest or reverse its course as soon as possible after its earliest clinical manifestations. This chapter will present the results of two pilot trials of a synthetic product, Copolymer I (Cop 1), which show promise of attaining the second objective.
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Myelin Basic Protein Expand Disability Status Scale Experimental Allergic Encephalomyelitis
Unable to display preview. Download preview PDF.
- Anderson S, Auguier A, Hauck W et al. (1980) Statistical methods for comparative studies. John Wiley and Sons, USA, pp 199–214Google Scholar
- Appel SH, Bornstein MB, Seegal BC, Murray MR (1962) The application of tissue culture to the study of experimental “allergic” encephalomyelitis. II. Immunological observations. Proc Int Cong Neuropath 2: 283Google Scholar
- Arnon R, Teitelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encepahlomyelitis and multiple sclerosis. Academic Press, New York, pp 105–117Google Scholar
- Bornstein MB (1973) The immunopathology of demyelinating disorders examined in organotypic cultures of mammalian central nerve tissue. In: HM Zimmerman (ed) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 69–90Google Scholar
- Paterson PY (1977) Autoimmune neurologic disease: Experimental animal systems and implications for multiple sclerosis. In: Talmage N (ed) Autoimmunity: Genetic, immunologic, virologic and clinical aspects. Academic Press, New York, pp 643–692Google Scholar
- Paterson PY (1978) The demyelinating diseases: Clinical and experimental studies in animals and man. In: Samter M, Alexander N, Rose B, Sherman WB, Talmage DW, Vaughn JH (eds) Immunologic diseases, 3rd edn. Little, Brown and Company, Boston, pp 1400–1435Google Scholar
- Paterson PY (1979) Neurological disorders. In: WJ Irvine (ed) Medical immunology. Teviot Scientific Publications, Edinburgh, pp 361–381Google Scholar
- Paterson PY (1980) The immunopathology of experimental allergic encephalomyelitis. In: Davison AN, Cuzner MC (eds) The suppression of experimental allergic encephalomyelitis in multiple sclerosis. Academic Press, New York, pp 11–30Google Scholar
- Raine CS, Bornstein MB (1970) Experimental allergic encephalomyelitis. A light and electron microscope study of remyelination and “sclerosis” in vitro. J Neuropath Exp Neurol 29: 552–574Google Scholar